Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study
Antonietta Romano, Paolo Angeli, Sara Piovesan, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 2, pp. 345-352
Closed Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1363
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat, Hélène Fontaine, Céline Dorival, et al.
The Lancet (2019) Vol. 393, Iss. 10179, pp. 1453-1464
Open Access | Times Cited: 563
Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents
Fasiha Kanwal, Jennifer R. Kramer, Steven M. Asch, et al.
Hepatology (2019) Vol. 71, Iss. 1, pp. 44-55
Closed Access | Times Cited: 229
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals
Mònica Pons, Sergio Rodríguez‐Tajes, Juan Ignacio Esteban, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 472-480
Closed Access | Times Cited: 173
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Don C. Rockey, Scott L. Friedman
Gastroenterology (2021) Vol. 160, Iss. 5, pp. 1502-1520.e1
Open Access | Times Cited: 107
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 90
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis
Ian Lockart, Malcolm Guan Hin Yeo, Behzad Hajarizadeh, et al.
Hepatology (2022) Vol. 76, Iss. 1, pp. 139-154
Open Access | Times Cited: 78
Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
Shira Perez, Antony Kaspi, Tom Domovitz, et al.
PLoS Genetics (2019) Vol. 15, Iss. 6, pp. e1008181-e1008181
Open Access | Times Cited: 136
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
Amit G. Singal, Joseph K. Lim, Fasiha Kanwal
Gastroenterology (2019) Vol. 156, Iss. 8, pp. 2149-2157
Open Access | Times Cited: 106
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Elisabetta Degasperi, Roberta D’Ambrosio, Massimo Iavarone, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 17, Iss. 6, pp. 1183-1191.e7
Closed Access | Times Cited: 101
Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
Federico Piñero, Manuel Mendizábal, Ezequiel Ridruejo, et al.
Liver International (2019) Vol. 39, Iss. 6, pp. 1033-1043
Closed Access | Times Cited: 85
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules
Zoe Mariñó, Anna Darnell, Sabela Lens, et al.
Journal of Hepatology (2019) Vol. 70, Iss. 5, pp. 874-884
Open Access | Times Cited: 81
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
Roberta D’Ambrosio, Elisabetta Degasperi, Maria Paola Anolli, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 302-310
Closed Access | Times Cited: 66
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Takanori Ito, Mindie H. Nguyen
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 413-428
Open Access | Times Cited: 35
Delisting HCV‐infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting
Giovanni Perricone, Christophe Duvoux, Marina Berenguer, et al.
Liver International (2018) Vol. 38, Iss. 12, pp. 2170-2177
Closed Access | Times Cited: 70
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
Luca Rinaldi, Riccardo Nevola, Gianluigi Franci, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1351-1351
Open Access | Times Cited: 69
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs
Elisabetta Degasperi, E. Galmozzi, Serena Pelusi, et al.
Hepatology (2020) Vol. 72, Iss. 6, pp. 1912-1923
Open Access | Times Cited: 60
Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma
Daisuke Uchida, Akinobu Takaki, Atsushi Oyama, et al.
Nutrients (2020) Vol. 12, Iss. 6, pp. 1576-1576
Open Access | Times Cited: 59
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
Luca Rinaldi, Alessandro Perrella, Maria Guarino, et al.
Journal of Translational Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 58
Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study
Gamal Shiha, Nasser Mousa, Reham Soliman, et al.
Journal of Viral Hepatitis (2020) Vol. 27, Iss. 7, pp. 671-679
Closed Access | Times Cited: 58
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort
Yasuhito Tanaka, Eiichi Ogawa, Chung‐Feng Huang, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 1023-1033
Closed Access | Times Cited: 57
Viral hepatitis: Milestones, unresolved issues, and future goals
Pietro Torre, Andrea Aglitti, Mario Masarone, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 28, pp. 4603-4638
Open Access | Times Cited: 42
Epidemiology and Elimination of HCV-Related Liver Disease
Pierre Pradat, Victor Virlogeux, Eric Trépo
Viruses (2018) Vol. 10, Iss. 10, pp. 545-545
Open Access | Times Cited: 58
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis
Maria Guarino, Luca Viganò, Francesca Romana Ponziani, et al.
Digestive and Liver Disease (2018) Vol. 50, Iss. 11, pp. 1105-1114
Closed Access | Times Cited: 55
Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis
Franco Dammacco, Gianfranco Lauletta, Sabino Russi, et al.
Clinical and Experimental Medicine (2018) Vol. 19, Iss. 1, pp. 1-21
Closed Access | Times Cited: 51
Page 1 - Next Page

Scroll to top